Not exact matches
Important
factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in
evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential
product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.
Since private lenders and banks that offer refinancing
evaluate multiple
factors to decide refinancing rates, they can not just advertise any singular rate on their refinancing
product.
However, it is important to consider
factors other than rates when
evaluating lenders, such as customer service and loan
product availability.
The team also had the opportunity to
evaluate a wide range of dietary
factors, including intake of fruits and vegetables, whole grains, nuts, dairy
products, and red and processed meats, along with key nutrients such as vitamin B6, vitamin B12, vitamin D, and others.
George notes, «Our goal in this trial was to
evaluate the safety of the gene therapy
product and secondarily, to determine if we could achieve levels of
factor IX that could decrease bleeding events in patients.»
Plus, I think how your skin looks in the morning when it's been free of makeup and environmental
factors can really help to
evaluate how well a
product is doing it's job.
A motivating
factor is that the expert or informed client will listen to their ideas and
evaluate the final
products.
The Industrial Engineer occupation covers positions managing, supervising, leading, and / or performing professional engineering and scientific work to determine,
evaluate, predict, and advise on effective ways for an organization to use its production
factors (i.e., people, equipment, materials, information, and energy) to make or process a
product or provide a service.
Our ultimate Buy Essay Online rating results from several
factors involved in
evaluating the quality of
products.
However, it is important to consider
factors other than rates when
evaluating lenders, such as customer service and loan
product availability.
As with any investment
product, defined contribution plan fiduciaries should
evaluate a wide range of
factors, including
product features and fiduciary considerations, to ensure they understand these different investment
products.
Since private lenders and banks that offer refinancing
evaluate multiple
factors to decide refinancing rates, they can not just advertise any singular rate on their refinancing
product.
Another important
factor in
evaluating which treats a retailer should carry is
product packaging.
These
factors should be considered by the user when
evaluating product performance or freedom from reactions.
Mr. Emison will discuss
factors to consider in
evaluating a potential
product liability case and will offer practical tips for identifying
products cases involving post-collision fires; airbag and seat belt failures; seatback failures and reclined seats; roof crush and vehicle rollovers; and tire, brake and other auto
product failures.
Rather, what they say is that these are among several
factors to be weighed in
evaluating whether someone who purports to review or endorse a
product actually has a «material connection» to the
product.
Analyze the present features of the
product and
evaluate which
factors appeal and which do not to the customers
Over half of respondents (52 %) said a strong
product line is the most important
factor when
evaluating top medical sales companies.
These responses were compiled and
evaluated to determine how medical sales salaries are impacted by
factors such as
products sold, company size, travel, experience, and even age and gender.
Among respondents of the 2016 Best Places to Work in Medical Sales survey, 52 percent said a strong
product line is the most important
factor when
evaluating top medical sales employers.
These
factors are similar to those you might use to determine which business to select from a local Yellow Pages directory, including proximity to where you are searching, expertise in the specific services or
products you need, and comprehensive business information to help
evaluate a business's suitability for you.
We would
evaluate many
factors to determine if you had a reason to believe that a
product is used for employment or other FCRA purposes, such as advertising placement and customer lists.